Yesterday we learned the exciting news that the FDA has granted Breakthrough Therapy designation for an investigational immunotherapy LLS is supporting through our Therapy Acceleration Program (TAP). The therapy, KTE-C19, being developed by Kite Pharma, is another example of a chimeric antigen receptor (CAR), an approach that genetically engineers patients’ immune T cells and reintroduces them into the body to kill cancer cells. KTE-C19 is crafted by removing patients' T cells and geneti...
Beat AML is a collaboration launched nearly three years ago by LLS and the Knight Cancer Institute at Oregon Health & Science University (OHSU), to go on the offenensive against acute myeloid leukemia (AML), a blood cancer with a poor prognosis and little change in the standard of care in 40 years. More than a dozen abstracts from the first phase of the initiative will be featured throughout the American Society of Hematology (#ASH15) Annual Meeting in Orlando over the next few days. #...
I would never have imagined that at the age of 29, I would be lying in intensive care fighting for my life with stage IV anaplastic large cell lymphoma (ALCL). What a wake-up call, literally! Nicknamed “Sleeping Beauty,” I woke up after three weeks to learn my true diagnosis following months of illness. By the time I opened my eyes, I had already undergone my first five-day round of chemotherapy…with five more sessions to go. It was going to be a long summer. But as it turns out, ...
